A Clinical Study of BAT4406F Injection in Patients With Minimal Change Disease/Focal Segmental Glomerulosclerosis

NCT07499700 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

RECRUITING

Status

192

Enrollment

INDUSTRY

Sponsor class

Conditions

Minimal Change Disease (MCD)
Focal Segmental Glomerulosclerosis (FSGS)

Interventions

DRUG: BAT4406F
OTHER: Placebos

Sponsor

Bio-Thera Solutions